PharmaCorp Rx Inc. faced a significant drop in its stock price, closing down 14.66% in the last trading session.
In a challenging day for PharmaCorp Rx Inc. (PCRX.V), the stock tumbled by 14.66%, closing at CA$0.49. This decline raises questions about the company's current standing and future prospects amidst a backdrop of mixed financial results and strategic initiatives.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
PharmaCorp Rx Inc.
PCRX.V
PCRX.V
PharmaCorp Rx Inc.
WealthAwesomeMarket cap
$87.04M
52W high
$0.58
52W low
$0.40
1W change
+16.00%
Beta
-4.27
Analyst Price Targets
Based on analyst covering PCRX
Wall Street analysts forecast PCRX stock price to rise 14.9% over the next 12 months.
Consensus
No RatingAvg. Target
C$0.67
+14.9% Upside
Current Price
C$0.58
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on PCRX's historical volatility
30-Day Vol
62.6%
Annualized
90-Day Vol
56.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.69
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$0.62 | C$0.50 โ C$0.76 |
| 60 trading days | C$0.65 | C$0.48 โ C$0.89 |
| 90 trading days | C$0.69 | C$0.48 โ C$1.01 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should exercise caution as PharmaCorp's recent performance could signal underlying issues despite previous growth announcements.
PharmaCorp's stock plummets 14.66% in one day.
With a market cap of CA$87 million, the stock's volatility raises concerns for investors looking for stability.
Bull case
PharmaCorp has shown some positive momentum in recent quarters, with increasing revenues and a focus on acquisitions that could strengthen its market position.
Bear case
The sharp decline in stock price may reflect investor worries about the company's profitability, highlighted by a negative profit margin of -0.0671 and a lack of recent positive news.
Market Reaction
The decline in PharmaCorp's stock price has raised eyebrows among investors, especially given the company's recent announcements of financial results that showed revenue growth. However, the market's reaction suggests that investors are cautious about the company's ability to maintain profitability, as indicated by its negative profit margin.
Financial Performance Overview
Despite reporting increased revenues in previous quarters, PharmaCorp's financial health remains a concern. The company's P/E ratio is not applicable, and its market cap is currently CA$87 million. Investors may be looking for clearer signs of sustainable profitability and growth before committing more capital.
Looking Ahead
As PharmaCorp Rx Inc. navigates this challenging period, investors should keep an eye on upcoming announcements and strategic moves. The company's focus on acquisitions and leadership changes could provide opportunities for recovery, but the recent stock performance underscores the need for caution.
Advertisement
